Company press releases and official corporate announcements.
A centralized feed of corporate press releases, earnings announcements, mergers, and official statements. Content is presented for informational purposes and may require additional analysis for market relevance.
23,607 total articles
IMUNON, Inc., a clinical-stage biotechnology firm, completed an exchange agreement converting $1.2 million of outstanding debt into Series B Preferred Stock, reducing debt by approximately 43% and increasing shareholders' equity. The transaction was done without issuing common stock or dilutive warrants, preserving financial flexibility and minimiz…
argenx SE announced new clinical, long-term, and real-world evidence data on its lead drug VYVGART for treating myasthenia gravis (MG) and chronic inflammatory demyelinating polyneuropathy (CIDP), along with promising results for pipeline drugs empasiprubart and adimanebart. The data show sustained efficacy, safety, and benefits of earlier treatmen…
Apyx Medical announced results from a prospective clinical study demonstrating that its Renuvion helium plasma radiofrequency technology improves biological markers of skin quality, including increased elastin and reduced inflammation. The study also showed high patient satisfaction and visible improvements in skin elasticity and radiance. These fi…
WeShop Holdings Limited (NASDAQ: WSHP), a community-owned shopping platform, announced the launch of its free app in the United States on November 16, 2026. Building on a successful UK pilot that generated £108.5 million in GMV, the app allows members to shop with hundreds of retailers, earn ShareBack rewards in the form of equity, and build owners…
Nayax Ltd and Getnet announced a global strategic partnership to accelerate integrated payments and commerce solutions for unattended business sectors such as vending machines and EV chargers across Latin America and Iberia. The collaboration enables operators to benefit from Nayax's payment technology combined with Getnet's local acquiring network…
3 E Network Technology Group Limited has commenced a global vendor evaluation and Request for Proposal process for procuring advanced hardware, including high-density server clusters, liquid cooling infrastructure, networking equipment, and storage systems, for its multi-megawatt AI compute center in Mikkeli, Finland. The initiative aims to deploy …
Mobilicom Limited, a Nasdaq-listed provider of cybersecure hardware and software solutions for drones and robotics, announced it will showcase its resilient communication technologies at the ADS ISR Drone Showcase in Virginia. This event attracts U.S. defense leaders and unmanned system operators, positioning Mobilicom to strengthen partnerships an…
Glass House Brands Inc., a leading U.S. cannabis company listed on NYSE and CBOE, announces the planned retirement of CFO Mark Vendetti, effective March 31, 2027. The company is conducting a search for a successor and highlights Vendetti's significant contributions over the past five years, supporting its growth in the cannabis sector.
SoundThinking, a Nasdaq-listed public safety technology company, has entered into a definitive merger agreement with Transom Capital Group. Shareholders will receive $8.00 per share in cash plus a non-transferable contingent value right (CVR) for up to $3.00 per share based on revenue milestones of its ShotSpotter and SafePointe products. The upfro…
PMGC Holdings Inc.'s subsidiary, NorthStrive Biosciences, has partnered with Charles River Laboratories to perform analytical testing on its engineered probiotic programs EL-22 and EL-32. This collaboration aims to strengthen product characterization and manufacturing consistency as these candidates advance toward clinical development, targeting mu…
DeFi Technologies Inc., through its subsidiary Valour, has launched the Valour Zcash (ZEC) SEK Exchange Traded Product (ETP) on the Spotlight Stock Market, enabling investors to gain regulated access to the privacy-focused digital asset Zcash via traditional brokerage accounts. This product expands Valour’s portfolio of over 100 digital asset ETPs …
Medicus Pharma has submitted an optimized seamless Phase 2b/3 registration-intent protocol for its investigational drug Teverelix®, a next-generation GnRH antagonist, to the FDA. The protocol targets advanced prostate cancer patients at increased cardiovascular risk and aims to create a more capital-efficient, partner-ready development pathway. Thi…
Mixed Martial Arts Group Limited (NYSE American: MMA), operating as MMA.INC, announced over $800,000 in additional annualized cash operating cost reductions since July 1, 2026, bringing total reductions to over $2.51 million. These reductions stem from technology delivery, AI-supported workflows, and operational discipline, enabling a leaner cost b…
FTI Consulting has appointed Jeffrey Hecht as Senior Managing Director to lead its Private Equity Tax and Advisory Services practice. Leveraging his extensive experience, Hecht will drive growth and enhance service offerings for private equity and multi-asset managers, focusing on transactions, fund formation, tax planning, and compliance.
Cognition Therapeutics announced a Type C meeting scheduled with the FDA to align on primary endpoints for its planned Phase 3 trial of Zervimesine (CT1812) targeting psychosis symptoms in people with dementia with Lewy bodies (DLB). The company seeks to finalize the trial design focused on hallucinations and delusions and aims to offer a disease-m…
Optimi Health Corp., a publicly traded commercial-stage psychedelic drug manufacturer, appointed Melanie Pump, a seasoned financial executive with 25+ years of experience in technology and emerging companies, to its Board of Directors. The company aims to leverage her expertise as it advances its position in the regulated psychedelic pharmaceutical…
Cellectar Biosciences presented data from a subset analysis of its Phase 2 CLOVER WaM trial showing high response rates in Waldenström Macroglobulinemia patients refractory or resistant to BTK inhibitor therapy using iopofosine I 131. The drug demonstrated a major response rate of 79.2%, overall response rate of 87.5%, and duration of response exce…
Cartesian Therapeutics announced encouraging additional retreatment data for Descartes-08, its investigational CAR-T cell therapy targeting myasthenia gravis (MG). Data from five retreated patients showed sustained and improved symptom relief up to 12 months after retreatment, with a mean 6.6-point reduction in MG-ADL scores. The therapy was well t…
TruGolf Holdings, Inc. announced that its executives along with Polymath Research Inc.'s CFO will present at The ThinkEquity Conference in New York. The presentation will focus on TruGolf’s established golf technology business and their expansion into tokenized financial infrastructure through the proposed acquisition of Polymath, a company special…
Polar Power announced a trial order for 50 propane-fueled DC generators from a major Tier 1 telecom operator in Southeast Asia, powering off-grid cell sites. This initial step could lead to a potential five-year program deploying up to 2,500 generators, representing approximately $60 million in revenue. The company's propane-based DC generators pro…
uniQure announced additional data from its ongoing Phase I/II trials of ifezuntirgene inilparvovec for Huntington's disease, demonstrating sustained slowing of disease progression at 36 and 48 months post-treatment. The gene therapy showed dose-dependent benefits on key clinical measures with a favorable safety profile, supporting its recent Biolog…
Unicycive Therapeutics announced the resubmission of its New Drug Application for oxylanthanum carbonate, an investigational treatment for hyperphosphatemia in dialysis patients with chronic kidney disease. The resubmission includes new Chemistry, Manufacturing, and Controls data from a different FDA-compliant drug product manufacturing vendor, alo…
Immix Biopharma, a Nasdaq-listed biotech company focused on AL Amyloidosis treatments, announced the pricing of an underwritten offering of approximately 11.36 million shares at $11.00 each, raising gross proceeds of $125 million. The funds will be used primarily to advance development of its lead CAR-T therapy, NXC-201, and for general corporate p…
Ocugen, Inc., a biotech company developing gene therapies for blindness diseases, will have its executive leadership present at two October 2026 investor and industry conferences focused on life sciences financing and gene therapy commercialization.
Invivyd announced positive topline results from its LIBERTY Phase 3 study showing that its monoclonal antibody candidate VYD2311 exhibits clinically and statistically superior safety and tolerability compared to an mRNA-based COVID-19 vaccine. The study also found that co-administration of VYD2311 with the mRNA vaccine did not reduce vaccine effect…
